TCF3
TCF3 (Transcription factor E2-alpha) is a protein that switches other genes on and off. The public catalogues list it as a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Non-Hodgkin lymphoma, Lung cancer and 3 more.
Overview
Transcriptional regulator involved in the initiation of neuronal differentiation and mesenchymal to epithelial transition. Heterodimers between TCF3 and tissue-specific basic helix-loop-helix (bHLH) proteins play major roles in determining tissue-specific cell fate during embryogenesis, like muscle or early B-cell differentiation. Together with TCF15, required for the mesenchymal to epithelial transition.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. Open Targets scores its association with cancer at 0.65 (direct and indirect evidence; datatypes literature 0.96, genetic association 0.00, somatic mutation 0.83).
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · TCF3 (Transcription factor E2-alpha) is a protein that switches other genes on and off. The public catalogues list it as a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Non-Hodgkin lymphoma, Lung cancer and 3 more.
- 1 · What it is
TCF3 (Transcription factor E2-alpha) is a protein that switches other genes on and off. The public catalogues list it as a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Non-Hodgkin lymphoma, Lung cancer and 3 more.
- 2 · What goes wrong in cancer
Transcriptional regulator involved in the initiation of neuronal differentiation and mesenchymal to epithelial transition.
- 3 · How drugs use it
No product in this corpus aims at TCF3 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
External identifiers
Sources: HGNC HGNC:11633 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P15923 (protein name, function text, keywords and locations (REST API)); CIViC gene TCF3 (1 evidence items, 0 assertions, 1 variants; diseases: Burkitt Lymphoma (GraphQL API, CC0)); Open Targets ENSG00000071564 (association with cancer (MONDO_0004992) 0.65; per-cancer scores at or above 0.5: non-small cell lung carcinoma 0.51, acute lymphoblastic leukaemia 0.58, non-Hodgkin lymphoma 0.61, lung cancer 0.53, leukaemia 0.61 (GraphQL API, CC0))
Biology
Transcriptional regulator involved in the initiation of neuronal differentiation and mesenchymal to epithelial transition. Heterodimers between TCF3 and tissue-specific basic helix-loop-helix (bHLH) proteins play major roles in determining tissue-specific cell fate during embryogenesis, like muscle or early B-cell differentiation. Together with TCF15, required for the mesenchymal to epithelial transition. Dimers bind DNA on E-box motifs: 5'-CANNTG-3'. Binds to the kappa-E2 site in the kappa immunoglobulin gene enhancer. Binds to IEB1 and IEB2, which are short DNA sequences in the insulin gene transcription control region. Location: Nucleus (UniProt). Locus 19p13.3 (HGNC).
- Leukaemia: Open Targets association 0.61 with leukaemia (MONDO_0005059)
- Non-Hodgkin lymphoma: Open Targets association 0.61 with non-Hodgkin lymphoma (MONDO_0018908)
- Lung cancer: Open Targets association 0.53 with lung cancer (MONDO_0008903)
- Burkitt lymphoma: CIViC evidence names this disease
- Acute lymphoblastic leukaemia: Open Targets association 0.58 with acute lymphoblastic leukaemia (MONDO_0004967)
- Non-small-cell lung cancer: Open Targets association 0.51 with non-small cell lung carcinoma (MONDO_0005233)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC holds 1 clinical evidence items on its variants; UniProt disease notes describe a translocation or gene fusion involving the gene. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"TCF3" OR ABSTRACT:"TCF3" OR TITLE:"transcription factor 3" OR ABSTRACT:"transcription factor 3" OR TITLE:"Transcription factor E2-alpha" OR ABSTRACT:"Transcription factor E2-alpha" OR TITLE:"E2A" OR ABSTRACT:"E2A" OR TITLE:"ITF1" OR ABSTRACT:"ITF1" OR TITLE:"MGC129647" OR ABSTRACT:"MGC129647") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TCF3, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetCCND3
Shares Burkitt lymphoma, Leukaemia (all types), Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia.
- TargetPBX1
Shares Leukaemia (all types), Lung cancer (all types), Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia.
- TargetJAK3
Shares Leukaemia (all types), Lung cancer (all types), Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia.
- TargetNT5C2
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia, CIViC.
- TargetP2RY8
Shares Burkitt lymphoma, Lung cancer (all types), Non-Hodgkin lymphoma (all types), CIViC.
- TargetPHF6
Shares Burkitt lymphoma, Leukaemia (all types), Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia.
- TargetARID5B
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia, Open Targets Platform.
- TargetBAK1
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia, Open Targets Platform.